AI use case

Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001

MindRank AI dosed the first patient in the MOBILE Phase III trial of MDR-001, its AI-designed oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes. The mul…

Browse catalog

At a glance

Core facts from this catalog record. Primary narrative lives in the hero above; full raw fields follow in the next section.

Company/Organization: MindRank AI
Industry: Biotechnology
Location: Shanghai

Record fields

Every column from the source row, in stable order. URLs open in a new tab.

Title

Phase III Trial of AI-Designed Oral GLP-1 Receptor Agonist MDR-001

Content

MindRank AI dosed the first patient in the MOBILE Phase III trial of MDR-001, its AI-designed oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes. The multicenter, randomized, double-blind, placebo-controlled trial enrolled approximately 750 patients across 50 sites in China. MDR-001 was discovered and optimized using MindRank proprietary AI platform Molecule Pro. The program progressed from project initiation to US IND clearance in 19 months and to Phase III in approximately 4.5 years.

URL

http://www.globenewswire.com/news-release/2026/02/26/3245165/0/en/MindRank-Announces-First-Patient-Dosed-in-Phase-III-Trial-of-AI-Designed-Oral-GLP-1-Receptor-Agonist-MDR-001.html

Continue exploring AI deployments in the catalog.

Back to use cases